Endocrine therapy is a treatment that blocks or lowers estrogen to slow or stop the growth of hormone-sensitive breast cancers. About 70-80% of breast cancers are fueled by hormones, and for those cancers, endocrine therapy cuts the recurrence rate roughly in half during the years you’re on it. It’s one of the most effective tools in breast cancer treatment, used both after surgery to prevent the cancer from returning and in advanced disease to control its spread.
How It Works
Most breast cancers have receptors on their cells that bind to estrogen, which signals the cancer to grow. Endocrine therapy interrupts that signal in one of three ways: blocking estrogen from attaching to cancer cells, destroying the estrogen receptors themselves, or reducing the amount of estrogen your body produces. The approach your oncologist recommends depends largely on your menopausal status and the specific characteristics of your cancer.
Your cancer is considered hormone receptor-positive if at least 1% of the cells in a biopsy sample test positive for estrogen or progesterone receptors on an immunohistochemistry test. That low threshold means even cancers with modest receptor levels may respond to endocrine therapy.
The Three Main Drug Classes
Endocrine therapy isn’t a single drug. It’s a category that includes several types of medications, each working differently.
Estrogen Receptor Blockers (SERMs)
These drugs compete with estrogen for a spot on the cancer cell’s receptor. When the drug occupies that spot, estrogen can’t get in, and the growth signal is blocked. Tamoxifen is the most widely used SERM and works in both premenopausal and postmenopausal women. Toremifene is an alternative used only in postmenopausal women. One important consideration: certain antidepressants can reduce tamoxifen’s effectiveness, so your oncologist may recommend a different approach if you take one of those medications.
Aromatase Inhibitors
After menopause, your ovaries stop being the main source of estrogen. Instead, an enzyme called aromatase converts other hormones into small amounts of estrogen in fat tissue, muscle, and other organs. Aromatase inhibitors (letrozole, anastrozole, and exemestane) block that enzyme, cutting off estrogen production at its source. These drugs are used primarily in postmenopausal women because premenopausal ovaries produce too much aromatase for the inhibitors to overcome on their own. Premenopausal women can take them, but only in combination with a drug that suppresses ovarian function.
Estrogen Receptor Degraders (SERDs)
Rather than simply blocking the receptor, SERDs destroy it. The drug binds to the estrogen receptor and destabilizes it, causing the cell to break down and dispose of the receptor entirely. Fulvestrant, given by injection, has been the standard SERD for years. In 2023, elacestrant became the first oral SERD approved for use in advanced, estrogen receptor-positive breast cancer, specifically in tumors with certain estrogen receptor gene mutations. This newer option is expanding treatment possibilities for people whose cancer has progressed on other therapies.
Premenopausal vs. Postmenopausal Treatment
Menopausal status is one of the biggest factors in choosing which endocrine therapy you’ll receive. Premenopausal women typically start with tamoxifen, since aromatase inhibitors aren’t effective against the high estrogen output of functioning ovaries. For higher-risk premenopausal patients, ovarian suppression (through medication or, less commonly, surgery) can be added, which then opens the door to aromatase inhibitors.
Postmenopausal women have more options. Aromatase inhibitors are often preferred because they tend to be slightly more effective in this group, though tamoxifen remains an alternative, particularly when side effects from aromatase inhibitors are difficult to manage.
How Long Treatment Lasts
Endocrine therapy is a long commitment. The standard course used to be five years, but current guidelines from the American Society of Clinical Oncology recommend extended treatment for many patients. Women with cancer that had spread to lymph nodes should be offered up to 10 years of endocrine therapy. Women with node-negative cancer may also benefit from extended treatment up to 10 years, depending on their individual risk of recurrence. Treatment beyond 10 years is not recommended, as the additional benefit appears too small to justify continuing.
That length matters because the protective effect continues even after you stop. In large trials of five years of tamoxifen, recurrence rates were about 50% lower during the treatment period and still about 30% lower during the five years after stopping. But breast cancer recurrence risk persists for at least 20 years, which is why longer treatment courses are now standard for higher-risk patients.
Side Effects by Drug Type
Because endocrine therapy works by reducing estrogen’s effects throughout the body, side effects often resemble menopause symptoms: hot flashes, night sweats, vaginal dryness, and mood changes. Beyond those shared effects, each drug class carries its own risks.
Tamoxifen increases the risk of blood clots, uterine cancer, and vaginal bleeding. These risks are relatively small but worth monitoring, especially in women over 50 or those with other clotting risk factors.
Aromatase inhibitors take a different toll. By deeply suppressing estrogen, they accelerate bone density loss and increase fracture risk. Joint pain and stiffness are among the most common complaints, affecting a significant number of women and sometimes becoming severe enough to make people consider stopping treatment. Aromatase inhibitors are also associated with higher cholesterol levels and a modest increase in cardiovascular events compared to tamoxifen.
Managing Joint Pain and Staying on Track
Joint pain from aromatase inhibitors is one of the top reasons women stop their treatment early, which is a real problem given how much these drugs reduce recurrence risk. The good news is that several strategies can help.
Regular exercise and weight management are consistently the most effective non-drug approaches. Research in patients with joint pain shows that a 10% reduction in body weight can improve joint function by nearly 30%. The combination of weight loss and exercise works better than either one alone. Water-based exercise (hydrotherapy) has also shown benefits for joint stiffness and pain.
Massage therapy, particularly Swedish technique, can reduce pain and improve function. Relaxation techniques, guided imagery combined with progressive muscle relaxation, and biofeedback are additional options that some patients find helpful for managing chronic discomfort. If these approaches aren’t enough, your oncologist can discuss switching to a different drug within the same class or changing to a different type of endocrine therapy altogether.
When Endocrine Therapy Is Used
Endocrine therapy serves different roles depending on the stage of your cancer. In early-stage breast cancer, it’s given after surgery (and often after chemotherapy or radiation) as adjuvant therapy, with the goal of killing any remaining cancer cells and reducing the chance of recurrence. This is the setting where 5 to 10 years of treatment is standard.
In advanced or metastatic breast cancer, endocrine therapy is often the first line of treatment, sometimes combined with targeted drugs that enhance its effectiveness. Here, the goal shifts from cure to controlling the disease for as long as possible while maintaining quality of life. When one endocrine therapy stops working, switching to a different type (for example, moving from an aromatase inhibitor to a SERD like fulvestrant or elacestrant) can provide additional disease control.